Imunotherapy opportunities in ovarian cancer

I. Zh. Shubina; Шубина И. Ж.; A. N. Gritsay; Грицай А. Н.; L. T. Mamedova; Мамедова Л. Т.; N. Yu. Sokolov; Соколов Н. Ю.; S. A. Kuznetsov; Кузнецов С. А.; M. V. Kiselevskiy; Киселевский М. В.; N. I. Lazareva; Лазарева Н. И.; V. V. Kuznetsov; Кузнецов В. В.; K. S. Titov; Титов К. С.; A. P. Nikolayev; Николаев А. П.

doi:10.17650/1994-4098-2013-0-3-4-110-113

Imunotherapy opportunities in ovarian cancer

Authors: Shubina I.Z.¹, Gritsay A.N.¹, Mamedova L.T.¹, Sokolov N.Y.², Kuznetsov S.A.¹, Kiselevskiy M.V.¹, Lazareva N.I.¹, Kuznetsov V.V.¹, Titov K.S.¹, Nikolayev A.P.¹
Affiliations:
1. N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
2. Acad. N.N. Burdenko Main Military Clinical Hospital, Ministry of Defense of the Russian Federation, Moscow
Issue: No 3-4 (2013)
Pages: 110-113
Section: GYNECOLOGY. TREATMENT
Published: 22.09.2013
URL: https://ojrs.abvpress.ru/ojrs/article/view/68
DOI: https://doi.org/10.17650/1994-4098-2013-0-3-4-110-113
ID: 68

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

In the last decade, accumulated evidence in favor of that ovarian cancer is an immunogenic tumor. Immunotherapy is aimed at stimulating the innate and adaptive immunity, may cause an effective response in patients with ovarian cancer. Various approaches immunotherapy include cytokinetherapy, use of monoclonal antibodies and cell therapy.